Open AccessPB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R‐CHOP: A REAL WORLD MOROCCAN EXPERIENCE
Author(s) -
Mahtat E. M.,
Ait Filali I.,
Allaoui M.,
Jennane S.,
El Maaroufi H.,
Oukabli M.,
Doghmi K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851344.33425.30
Subject(s) - chemoimmunotherapy , rituximab , diffuse large b cell lymphoma , medicine , germinal center , oncology , lymphoma , population , log rank test , chop , proportional hazards model , multivariate analysis , progression free survival , immunohistochemistry , survival analysis , overall survival , b cell , immunology , antibody , environmental health